Pharmacogenomics of Stimulant Treatment Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-24
SponsorUniversity of Calgary
About this trial
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Eligibility criteria
Qualifiers
Aged 6 - 24 years.
Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
Primary diagnosis of ADHD (all types).
Starting Methylphenidate (excluding immediate release forms) treatment.
Disqualifiers
Co-occurring psychotic, bipolar or eating disorders.
Significant risk of suicide.
An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov